Retatrutide research reference

Retatrutide is an investigational molecule designed as a GIP, GLP-1 and glucagon receptor triple agonist. This page is a research reference, not a treatment or dosing guide.

What retatrutide is

Retatrutide is described by its developer, Eli Lilly, as an investigational triple hormone receptor agonist acting at the GIP, GLP-1 and glucagon receptors. As of October 3, 2026, Lilly continues to describe retatrutide as investigational and not available for public use.

Why status matters

Investigational status is different from FDA approval. Research material bearing the name retatrutide should not be described as an approved medicine, generic equivalent, compounded substitute or consumer treatment.

Research-use documentation

For lawful laboratory work, researchers should be able to identify the material, lot, stated specifications and any analytical documentation associated with that lot. Driftless Research is building its catalog around that documentation-first approach.

Primary references

• Eli Lilly: What to know about retatrutide — current investigational-status overview.
• U.S. FDA: concerns with unapproved GLP-1 drugs — includes current regulatory discussion of retatrutide and cagrilintide.